Merck: FDA Grants Priority Review For SBLAs For KEYTRUDA, KEYTRUDA QLEX, Each With Padcev

AI Briefing

• – Merck's KEYTRUDA and KEYTRUDA QLEX receive FDA priority review for potential new indications.
• – The FDA granted priority review for supplemental Biologics License Applications for KEYTRUDA and KEYTRUDA QLEX.
• – Merck's anti-PD-1 therapy may receive accelerated approval for new uses.